Dr. David B. Nash, Dean of the Jefferson College of Population Health, talks about the national opioid emergency with Lyn Chesna, Managing Editor of P&T. Dr. Nash describes how population health professionals, big pharma, and nonprofit organizations, such as the 1889 Foundation and the Pharmacy Quality Alliance, are addressing the issue.
First drug approved to treat MS in patients as young as 10 years old
Six states will also participate in the litigation
Drug used in combination with bortezomib, melphalan, and prednisone
Scientists find new molecular target for developing safer pain medications
Azar, Striking an Aggressive Tone, Suggests Trump Will Call Out Drug Companies Behind Major Price Hikes
HHS Secretary also addresses drug-related Medicare issues
Kymriah now indicated for relapsed or refractory diffuse large B cell lymphoma
This is the third indication granted for the co-administered drugs
Approval based on clinical studies and real-world evidence
Lowest, total-volume preparation bowel cleanser available in U.S.
Gemcitabine flush is cost-effective and potentially “practice-changing”
Perspectives on the Opioid Crisis With Dr. David B. Nash
April 2018 interview